Neurocrine Bio. (NBIX) PT Lowered to $140 at BMO Capital
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $152.72 +1.26%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BMO Capital analyst Evan David Seigerman lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $140.00 (from $145.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley
- LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
- Neurocrine's Ingrezza study shows quality-of-life gains in TD patients
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
